Answers are grounded in this paper and cite their sources.
In 2018, Baricitinib was approved by the Food and Drig Administration (FDA) for the treatment of rheumatoid arthritis. Baricitinib exerts its action by targeting Janus kinases (JAK). In this study, we describe the necessary steps for preparing the drug using two alternative routes.
No takes yet. Share an insight, caveat, or question.
Mayence et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: